BridgeBio Oncology Therapeutics, Inc. (BBOT) shareholders
BBOTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.14−0.21 (-8.94%)
Close on Nov 13, 2026Market cap $171.57MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
73.8%
59M of 80M shares
Institutional holders
66
17 new, 18 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Bihua Chen Joint filing with Cormorant Global Healthcare Master Fund, LP (7.59%), Cormorant Global Healthcare GP, LLC (7.59%) and 4 more | 17,878,594 | 22.32% | 13D (active) amendment | Jul 1, 2026 |
| BridgeBio Pharma, Inc. Joint filing with BridgeBio Pharma LLC (17.50%) | 13,878,554 | 17.50% | 13D (active) | Aug 11, 2025 |
| James E. Flynn Joint filing with Deerfield Management Company, L.P. (6.17%) | 4,885,446 | 6.17% | 13G (passive) | Aug 11, 2025 |
| Tan Kuangming Joint filing with BC Global Opportunities IX LP (5.50%), BC General Partner, LP (5.50%) and 1 more | 4,365,747 | 5.50% | 13G (passive) | Sep 4, 2025 |
| BlackRock Portfolio Management LLC | 1,498,865 | 7.90% | 13G (passive) | Mar 31, 2025 |
| Adage Capital Partners GP, L.L.C. Joint filing with Adage Capital Partners, L.P. (7.40%), Adage Capital Management, L.P. (7.40%) and 2 more | 1,400,000 | 7.40% | 13G (passive) | Feb 13, 2024 |
| T. Rowe Price Associates, Inc. | 1,127,598 | 6.00% | 13G (passive) | Nov 14, 2024 |
| Sculptor Capital Management, Inc. Joint filing with Sculptor Capital LP (5.12%), Sculptor Capital II LP (5.12%) and 4 more | 967,460 | 5.12% | 13G (passive) | Jul 17, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BBOT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 17,878,594 | 22.30% | $136.23M | – | 6.98% |
| Deerfield Management Company, L.P. (Series C) | 4,885,446 | 6.09% | $37.23M | – | 0.39% |
| Omega Fund Management, LLC | 3,289,661 | 4.10% | $25.07M | – | 13.50% |
| Alphabet Inc. | 2,823,126 | 3.52% | $21.51M | – | 0.02% |
| EcoR1 Capital, LLC | 2,823,126 | 3.52% | $21.51M | – | 1.05% |
| Wellington Management Group Llp | 2,789,302 | 3.48% | $21.25M | −29,046 | 0.00% |
| Enavate Sciences Gp, LLC | 2,626,946 | 3.28% | $20.02M | – | 5.80% |
| Citadel Advisors LLC | 2,617,827 | 3.27% | $19.95M | +89,065 | 0.00% |
| Novo Holdings A/S | 2,250,000 | 2.81% | $17.15M | +64,077 | 1.00% |
| BlackRock, Inc. | 2,154,040 | 2.69% | $16.41M | +65,743 | 0.00% |
| Vanguard Capital Management LLC | 2,005,649 | 2.50% | $15.28M | +1,467,208 | 0.00% |
| Laurion Capital Management LP | 2,002,701 | 2.50% | $15.26M | +80,045 | 0.39% |
| Armistice Capital, LLC | 1,764,000 | 2.20% | $13.44M | +436,000 | 0.16% |
| State Street Corp | 1,036,569 | 1.29% | $7.90M | +810,291 | 0.00% |
| Aisling Capital Management LP | 1,018,018 | 1.27% | $7.76M | – | 1.64% |
| Opaleye Management Inc. | 700,000 | 0.87% | $5.33M | +646,718 | 0.48% |
| Geode Capital Management, LLC | 622,351 | 0.78% | $4.74M | +43,117 | 0.00% |
| Granahan Investment Management, LLC | 558,526 | 0.70% | $4.26M | +327,486 | 0.15% |
| Sphera Funds Management Ltd. | 460,985 | 0.57% | $3.51M | New | 0.46% |
| Adage Capital Partners Gp, L.L.C. | 400,000 | 0.50% | $3.05M | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 66 | 59M | 73.8% | 17 / 21 | 15 / 18 | 6M | 4M |
| Q1 2026 | 67 | 57M | 71.7% | 23 / 20 | 11 / 7 | 5M | 5M |
| Q4 2025 | 53 | 58M | 72.7% | 15 / 12 | 12 / 4 | 3M | 1M |
| Q3 2025 | 42 | 57M | 70.9% | 24 / 10 | 7 / 15 | 46M | 6M |
| Q2 2025 | 34 | 17M | 20.9% | 7 / 7 | 4 / 4 | 2M | 2M |
| Q1 2025 | 31 | 16M | 20.6% | 3 / 9 | 6 / 4 | 1M | 1M |
| Q4 2024 | 32 | 16M | 20.5% | 5 / 7 | 3 / 3 | 1M | 0M |
| Q3 2024 | 31 | 16M | 20.4% | 3 / 4 | 3 / 2 | 2M | 0M |
| Q2 2024 | 31 | 16M | 20.4% | 2 / 5 | 3 / 0 | 0M | 0M |
| Q1 2024 | 29 | 16M | 20.0% | 29 / 0 | 0 / 0 | 16M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
38 funds held BBOT in Q2 2026, 62% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of BBOT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,422,900 | 1.77% | $10.84M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 813,301 | 1.01% | $6.20M | 0.06% | Jun 30, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 673,766 | 0.84% | $6.04M | 0.10% | May 29, 2026 |
| Vanguard Extended Market Index Fund | 539,581 | 0.67% | $4.11M | 0.00% | Jun 30, 2026 |
| iShares Biotechnology ETF | 306,024 | 0.38% | $2.33M | 0.03% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 250,892 | 0.31% | $2.25M | 0.01% | May 31, 2026 |
| Select Biotechnology Portfolio | 240,300 | 0.30% | $2.16M | 0.04% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 227,258 | 0.28% | $2.04M | 0.01% | May 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 222,512 | 0.28% | $1.70M | 0.01% | Jun 30, 2026 |
| Victory Small Cap Stock Fund | 134,743 | 0.17% | $1.09M | 0.11% | Jul 31, 2026 |
| Tema Oncology ETF | 93,339 | 0.12% | $837.25K | 0.48% | May 31, 2026 |
| Fidelity Total Market Index Fund | 90,376 | 0.11% | $810.67K | 0.00% | May 31, 2026 |
| Royce Micro-Cap Fund | 87,617 | 0.11% | $667.64K | 0.16% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 72,932 | 0.09% | $654.20K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 49,459 | 0.06% | $443.65K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Pedro Beltran | President and CEO, Director | 43,529 | 0.05% | Oct 5, 2026 |
| Eli M. Wallace | Chief Executive Officer, Director | – | – | Jan 5, 2026 |
| Marc Cobo | Principal Accounting Officer | 13,812 | 0.02% | Oct 23, 2026 |
| Idan Elmelech | COO & Principal Financial Ofcr | 14,152 | 0.02% | Oct 5, 2026 |
| Yong Ben | Chief Med & Dev Officer | 43,529 | 0.05% | Oct 5, 2026 |
| Caleb Tripp | Chief Financial Officer | – | – | Aug 11, 2025 |
| Nebojsa Obradovic | Chief Legal Officer | – | – | Aug 11, 2025 |
| Bihua Chen | Director, 10% owner | 18,782,194 | 23.43% | Jul 6, 2026 |
| Praveen P. Tipirneni | Director | – | – | Jun 18, 2026 |
| Neil Kumar | Director | – | – | Jun 18, 2026 |
| Peter F. Lebowitz | Director | – | – | Jun 18, 2026 |
| Frank McCormick | Director | – | – | Jun 18, 2026 |
| Jake Bauer | Director | – | – | Jun 18, 2026 |
| Raymond J. Kelleher | Director | – | – | Jun 18, 2026 |
| Michelle Doig | Director | – | – | Aug 18, 2025 |
| Holdings II LLC Helix | Director, 10% owner | 4,989,000 | 6.22% | Feb 10, 2025 |
| Uneek Mehra | – | 22,806 | 0.03% | May 5, 2026 |
| Pharma LLC BridgeBio | 10% owner | 13,805,126 | 17.22% | Oct 16, 2025 |
| BridgeBio Pharma, Inc. | 10% owner | 14,589,846 | 18.20% | Oct 16, 2025 |
| Albert A. Holman III | – | 30,000 | 0.04% | Aug 11, 2025 |
| Mark C. McKenna | – | 30,000 | 0.04% | Aug 11, 2025 |
| John P. Schmid | – | 30,000 | 0.04% | Aug 11, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Marc Cobo Principal Accounting Officer | Oct 21, 2026 | Tax withholding | −203 | $2.68 | $544 | 13,812 |
| Marc Cobo Principal Accounting Officer | Oct 1, 2026 | Tax withholding | −126 | $3.94 | $496 | 14,015 |
| Idan Elmelech COO & Principal Financial Ofcr | Oct 1, 2026 | Tax withholding | −343 | $3.94 | $1.35K | 14,152 |
| Pedro Beltran President and CEO, Director | Oct 1, 2026 | Tax withholding | −1,047 | $3.94 | $4.13K | 43,529 |
| Yong Ben Chief Med & Dev Officer | Oct 1, 2026 | Tax withholding | −1,047 | $3.94 | $4.13K | 43,529 |
| Marc Cobo Principal Accounting Officer | Sep 10, 2026 | Tax withholding | −203 | $5.52 | $1.12K | 14,141 |
| Marc Cobo Principal Accounting Officer | Sep 10, 2026 | Award | +9,038 | – | – | 14,344 |
| Marc Cobo Principal Accounting Officer | Jul 1, 2026 | Tax withholding | −125 | $7.80 | $975 | 5,306 |
| Yong Ben Chief Med & Dev Officer | Jul 1, 2026 | Tax withholding | −1,047 | $7.80 | $8.17K | 44,576 |
| Bihua Chen Director, 10% owner | Jul 1, 2026 | Other | −4,528,186 | – | – | 0 |
| Bihua Chen Director, 10% owner | Jul 1, 2026 | Other | +2,692,459 | – | – | 4,879,995 |
| Bihua Chen Director, 10% owner | Jul 1, 2026 | Other | +1,704,862 | – | – | 5,010,332 |
| Bihua Chen Director, 10% owner | Jul 1, 2026 | Other | +130,865 | – | – | 6,083,221 |
| Idan Elmelech COO & Principal Financial Ofcr | Jul 1, 2026 | Tax withholding | −343 | $7.80 | $2.68K | 14,495 |
| Pedro Beltran President and CEO, Director | Jul 1, 2026 | Tax withholding | −1,047 | $7.80 | $8.17K | 44,576 |
| Yong Ben Chief Med & Dev Officer | Apr 1, 2026 | Tax withholding | −1,047 | $9.03 | $9.45K | 45,623 |
| Uneek Mehra – | Apr 1, 2026 | Tax withholding | −524 | $9.03 | $4.73K | 22,806 |
| Pedro Beltran President and CEO, Director | Apr 1, 2026 | Tax withholding | −1,047 | $9.03 | $9.45K | 45,623 |
| Yong Ben Chief Med & Dev Officer | Mar 10, 2026 | Award | +46,670 | – | – | 46,670 |
| Uneek Mehra Chief Financial Officer | Mar 10, 2026 | Award | +23,330 | – | – | 23,330 |
| Pedro Beltran Chief Scientific Officer | Mar 10, 2026 | Award | +46,670 | – | – | 46,670 |
| BridgeBio Pharma, Inc. 10% owner | Oct 10, 2025 | Other | +784,720 | – | – | 14,589,846 |
| Bihua Chen Director, 10% owner | Aug 11, 2025 | Award | +639,110 | $10.72 | $6.85M | 1,542,710 |
| Bihua Chen Director, 10% owner | Aug 11, 2025 | Award | +5,598,425 | $10.72 | $60.02M | 5,667,785 |
| Bihua Chen Director, 10% owner | Aug 11, 2025 | Award | +1,905,046 | – | – | 1,905,046 |
| Bihua Chen Director, 10% owner | Aug 11, 2025 | Award | +1,762,760 | – | – | 3,305,470 |
| Bihua Chen Director, 10% owner | Aug 11, 2025 | Award | +284,571 | – | – | 5,952,356 |
| Bihua Chen Director, 10% owner | Aug 11, 2025 | Award | +760,496 | $10.72 | $8.15M | 2,187,536 |
| Bihua Chen Director, 10% owner | Aug 11, 2025 | Option exercise | +4,172,126 | – | – | 4,681,126 |
| Bihua Chen Director, 10% owner | Aug 11, 2025 | Returned to company | −152,940 | – | – | 4,528,186 |
| Mark C. McKenna – | Aug 11, 2025 | Option exercise | +30,000 | – | – | 30,000 |
| Albert A. Holman III – | Aug 11, 2025 | Option exercise | +30,000 | – | – | 30,000 |
| John P. Schmid – | Aug 11, 2025 | Option exercise | +30,000 | – | – | 30,000 |
| Bihua Chen CEO and Chairperson, Director, 10% owner | Feb 13, 2024 | Buy | +903,600 | $10.00 | $9.04M | 903,600 |
| Bihua Chen CEO and Chairperson, Director, 10% owner | Feb 13, 2024 | Buy | +1,427,040 | $10.00 | $14.27M | 1,427,040 |
| Bihua Chen CEO and Chairperson, Director, 10% owner | Feb 13, 2024 | Buy | +69,360 | $10.00 | $693.60K | 69,360 |
| Bihua Chen CEO and Chairperson, Director, 10% owner | Feb 13, 2024 | Award | +509,000 | $10.00 | $5.09M | 509,000 |
| Holdings II LLC Helix Director, 10% owner | Feb 13, 2024 | Award | +509,000 | $10.00 | $5.09M | 509,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
8.18%
3M shares short
Days to cover
5.1
At 1M shares a day
Change since last report
-9.8%
From 4M shares
Short volume, 20 days
30.1%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of BridgeBio Oncology Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 81,348 shares on Aug 28, 2026 over the last 90 days.
See a number that looks wrong?